WallStreetZenWallStreetZen

NASDAQ: VXRT
Vaxart Inc Stock

$1.30+0.01 (+0.78%)
Updated Mar 28, 2024
VXRT Price
$1.30
Fair Value Price
$0.17
Market Cap
$226.02M
52 Week Low
$0.53
52 Week High
$1.59
P/E
-2.28x
P/B
3.91x
P/S
11.24x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.38M
Earnings
-$82.47M
Gross Margin
100%
Operating Margin
-1,114.03%
Profit Margin
-1,117.6%
Debt to Equity
0.59
Operating Cash Flow
-$70M
Beta
0.54
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A

VXRT Overview

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VXRT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VXRT ($1.30) is overvalued by 668.34% relative to our estimate of its Fair Value price of $0.17 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VXRT ($1.30) is not significantly undervalued (668.34%) relative to our estimate of its Fair Value price of $0.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VXRT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VXRT due diligence checks available for Premium users.

Be the first to know about important VXRT news, forecast changes, insider trades & much more!

VXRT News

Valuation

VXRT fair value

Fair Value of VXRT stock based on Discounted Cash Flow (DCF)
Price
$1.30
Fair Value
$0.17
Overvalued by
668.34%
VXRT ($1.30) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VXRT ($1.30) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VXRT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VXRT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.28x
Industry
14.26x
Market
44.51x

VXRT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.91x
Industry
6.21x
VXRT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VXRT's financial health

Profit margin

Revenue
$3.2M
Net Income
-$17.4M
Profit Margin
-535.4%
VXRT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VXRT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$91.8M
Liabilities
$34.0M
Debt to equity
0.59
VXRT's short-term assets ($45.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VXRT's short-term assets ($45.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VXRT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VXRT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$13.5M
Investing
$15.1M
Financing
-$66.0k
VXRT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

VXRT vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
VXRT$226.02M+0.78%-2.28x3.91x
ATOS$225.55M-1.64%-7.50x2.30x
GTHX$225.50M-3.36%-4.65x6.37x
DSGN$227.67M+3.07%-3.39x0.82x
CGEN$228.11M+1.57%-12.29x3.48x

Vaxart Stock FAQ

What is Vaxart's quote symbol?

(NASDAQ: VXRT) Vaxart trades on the NASDAQ under the ticker symbol VXRT. Vaxart stock quotes can also be displayed as NASDAQ: VXRT.

If you're new to stock investing, here's how to buy Vaxart stock.

What is the 52 week high and low for Vaxart (NASDAQ: VXRT)?

(NASDAQ: VXRT) Vaxart's 52-week high was $1.59, and its 52-week low was $0.53. It is currently -18.24% from its 52-week high and 145.28% from its 52-week low.

How much is Vaxart stock worth today?

(NASDAQ: VXRT) Vaxart currently has 173,861,684 outstanding shares. With Vaxart stock trading at $1.30 per share, the total value of Vaxart stock (market capitalization) is $226.02M.

Vaxart stock was originally listed at a price of $224.82 in Dec 31, 1997. If you had invested in Vaxart stock at $224.82, your return over the last 26 years would have been -99.42%, for an annualized return of -17.98% (not including any dividends or dividend reinvestments).

How much is Vaxart's stock price per share?

(NASDAQ: VXRT) Vaxart stock price per share is $1.30 today (as of Mar 28, 2024).

What is Vaxart's Market Cap?

(NASDAQ: VXRT) Vaxart's market cap is $226.02M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Vaxart's market cap is calculated by multiplying VXRT's current stock price of $1.30 by VXRT's total outstanding shares of 173,861,684.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.